Eli Lilly Q1 2026 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: seekingalpha
- Significant Profitability Increase: Eli Lilly's Q1 2026 non-GAAP EPS of $8.55 surpassed expectations by $1.76, indicating strong profitability that is likely to drive stock price upward.
- Robust Revenue Growth: The company reported Q1 revenue of $19.8 billion, a 55.5% year-over-year increase, exceeding expectations by $2 billion, primarily driven by volume growth despite lower prices for Mounjaro and Zepbound, which will enhance investor confidence.
- Upgraded Full-Year Outlook: Eli Lilly raised its FY26 revenue guidance from $80-$83 billion to $82-$85 billion, reflecting optimism about future performance, while also increasing EPS guidance from $33.50-$35.00 to $35.50-$37.00, demonstrating management's confidence in market demand.
- Impact of R&D Expenses: The reported EPS for Q1 included $0.52 of acquired IPR&D charges, down from $1.72 in Q1 2025, indicating a strategic adjustment in R&D investment that may enhance overall profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 874.000
Low
950.00
Averages
1192
High
1500
Current: 874.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
Significant Premarket Trading Moves by Multiple Companies
- Meta's CapEx Increase: Meta Platforms raised its full-year capital expenditure guidance to between $125 billion and $145 billion, causing a 9% drop in stock price due to heightened concerns over AI spending, which negatively impacts investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's first-quarter earnings and revenue exceeded analyst expectations, leading to an almost 8% stock increase, while the company raised its full-year sales outlook to between $82 billion and $85 billion, indicating robust market demand.
- Alphabet's Impressive Earnings: Alphabet reported first-quarter revenue of $109.9 billion, surpassing the $107.2 billion expected by analysts, resulting in a 7.4% stock increase, with Google Cloud revenue soaring 63% year-over-year, showcasing strong growth potential in its cloud business.
- Royal Caribbean's Solid Results: Royal Caribbean's first-quarter adjusted earnings came in at $3.60 per share, exceeding the $3.20 expected by analysts, and despite slightly missing revenue expectations, the stock rose 7%, reflecting market confidence in its financial health.
See More
Eli Lilly Raises Annual Profit Forecast Amid Strong Drug Demand
- Profit Forecast Increase: Eli Lilly raised its adjusted earnings per share forecast for 2023 to between $35.50 and $37.00, up from the previous range of $33.50 to $35.00, reflecting strong confidence in future performance.
- Q1 Results Beat Expectations: The company's first-quarter results exceeded market expectations due to steady demand for weight-loss drug Zepbound and diabetes drug Mounjaro, indicating robust product performance in the market.
- New Drug Rollout Challenges: The recently launched oral weight-loss drug Foundayo was prescribed only 3,707 times in the week ending April 17, falling short of analysts' expectations of around 8,000, highlighting challenges in market penetration.
- Market Share Competition: CEO David Ricks stated that Foundayo will significantly expand the number of people benefiting from GLP-1s, with investors closely watching its ability to capture market share from rival Novo Nordisk.
See More
Eli Lilly Q1 2026 Earnings Exceed Expectations
- Significant Profitability Increase: Eli Lilly's Q1 2026 non-GAAP EPS of $8.55 surpassed expectations by $1.76, indicating strong profitability that is likely to drive stock price upward.
- Robust Revenue Growth: The company reported Q1 revenue of $19.8 billion, a 55.5% year-over-year increase, exceeding expectations by $2 billion, primarily driven by volume growth despite lower prices for Mounjaro and Zepbound, which will enhance investor confidence.
- Upgraded Full-Year Outlook: Eli Lilly raised its FY26 revenue guidance from $80-$83 billion to $82-$85 billion, reflecting optimism about future performance, while also increasing EPS guidance from $33.50-$35.00 to $35.50-$37.00, demonstrating management's confidence in market demand.
- Impact of R&D Expenses: The reported EPS for Q1 included $0.52 of acquired IPR&D charges, down from $1.72 in Q1 2025, indicating a strategic adjustment in R&D investment that may enhance overall profitability.
See More
Eli Lilly Raises Full-Year Outlook After Strong Q1 Results
- Significant Revenue Growth: Eli Lilly reported $19.8 billion in Q1 revenue, reflecting approximately 56% year-over-year growth, exceeding market expectations by $2 billion, demonstrating the strong performance of its GLP-1 product line, particularly as volume gains offset price declines.
- Outstanding Mounjaro Performance: Mounjaro contributed $8.7 billion to the topline with approximately 125% year-over-year growth, significantly surpassing analysts' projections of $7.21 billion, indicating robust demand in the obesity market and further solidifying Eli Lilly's leadership position.
- New Product Launch: CEO David Ricks highlighted the recent launch of the oral weight loss therapy Foundayo, which is expected to meaningfully expand the number of individuals benefiting from GLP-1s, directly competing with Novo Nordisk's Wegovy and indicating further expansion potential in the weight loss market.
- Optimistic Future Outlook: Eli Lilly projects revenue between $82 billion and $85 billion for 2026, with non-GAAP EPS expected to be between $35.50 and $37.00, an upward revision from previous estimates, reflecting the company's confidence in future growth.
See More
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
Significant Premarket Trading Moves by Multiple Companies
- Meta's CapEx Increase: Meta Platforms raised its full-year capital expenditure guidance to between $125 billion and $145 billion, causing a 9% drop in stock price due to heightened concerns over AI spending, which negatively impacts investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's first-quarter earnings and revenue exceeded analyst expectations, leading to an almost 8% stock increase, while the company raised its full-year sales outlook to between $82 billion and $85 billion, indicating robust market demand.
- Alphabet's Impressive Earnings: Alphabet reported first-quarter revenue of $109.9 billion, surpassing the $107.2 billion expected by analysts, resulting in a 7.4% stock increase, with Google Cloud revenue soaring 63% year-over-year, showcasing strong growth potential in its cloud business.
- Royal Caribbean's Solid Results: Royal Caribbean's first-quarter adjusted earnings came in at $3.60 per share, exceeding the $3.20 expected by analysts, and despite slightly missing revenue expectations, the stock rose 7%, reflecting market confidence in its financial health.
See More
Eli Lilly Raises Annual Profit Forecast Amid Strong Drug Demand
- Profit Forecast Increase: Eli Lilly raised its adjusted earnings per share forecast for 2023 to between $35.50 and $37.00, up from the previous range of $33.50 to $35.00, reflecting strong confidence in future performance.
- Q1 Results Beat Expectations: The company's first-quarter results exceeded market expectations due to steady demand for weight-loss drug Zepbound and diabetes drug Mounjaro, indicating robust product performance in the market.
- New Drug Rollout Challenges: The recently launched oral weight-loss drug Foundayo was prescribed only 3,707 times in the week ending April 17, falling short of analysts' expectations of around 8,000, highlighting challenges in market penetration.
- Market Share Competition: CEO David Ricks stated that Foundayo will significantly expand the number of people benefiting from GLP-1s, with investors closely watching its ability to capture market share from rival Novo Nordisk.
See More
Eli Lilly Q1 2026 Earnings Exceed Expectations
- Significant Profitability Increase: Eli Lilly's Q1 2026 non-GAAP EPS of $8.55 surpassed expectations by $1.76, indicating strong profitability that is likely to drive stock price upward.
- Robust Revenue Growth: The company reported Q1 revenue of $19.8 billion, a 55.5% year-over-year increase, exceeding expectations by $2 billion, primarily driven by volume growth despite lower prices for Mounjaro and Zepbound, which will enhance investor confidence.
- Upgraded Full-Year Outlook: Eli Lilly raised its FY26 revenue guidance from $80-$83 billion to $82-$85 billion, reflecting optimism about future performance, while also increasing EPS guidance from $33.50-$35.00 to $35.50-$37.00, demonstrating management's confidence in market demand.
- Impact of R&D Expenses: The reported EPS for Q1 included $0.52 of acquired IPR&D charges, down from $1.72 in Q1 2025, indicating a strategic adjustment in R&D investment that may enhance overall profitability.
See More
Eli Lilly Raises Full-Year Outlook After Strong Q1 Results
- Significant Revenue Growth: Eli Lilly reported $19.8 billion in Q1 revenue, reflecting approximately 56% year-over-year growth, exceeding market expectations by $2 billion, demonstrating the strong performance of its GLP-1 product line, particularly as volume gains offset price declines.
- Outstanding Mounjaro Performance: Mounjaro contributed $8.7 billion to the topline with approximately 125% year-over-year growth, significantly surpassing analysts' projections of $7.21 billion, indicating robust demand in the obesity market and further solidifying Eli Lilly's leadership position.
- New Product Launch: CEO David Ricks highlighted the recent launch of the oral weight loss therapy Foundayo, which is expected to meaningfully expand the number of individuals benefiting from GLP-1s, directly competing with Novo Nordisk's Wegovy and indicating further expansion potential in the weight loss market.
- Optimistic Future Outlook: Eli Lilly projects revenue between $82 billion and $85 billion for 2026, with non-GAAP EPS expected to be between $35.50 and $37.00, an upward revision from previous estimates, reflecting the company's confidence in future growth.
See More
